New Research Sheds Light on Weight Gain After GLP-1 Discontinuation

A new study published in Obesity Sciences & Practices has identified promising strategies for mitigating weight gain experienced by patients after stopping GLP-1 treatment. GLP-1 medications are commonly prescribed for long-term management of obesity and type 2 diabetes, but a significant number of users discontinue the medication within a year.

High Rate of Discontinuation and Its Consequences

The study notes that 20% to 50% of people prescribed GLP-1s stop the treatment in less than a year. Reasons for discontinuation include high costs, limits in insurance coverage, side effects, and patient preference. Growing popularity of GLP-1s has pushed some insurance companies to stop covering these drugs for weight loss, increasing the number of patients discontinuing treatment. Previous research has shown that most patients regain at least half of the weight lost through GLP-1s, often quickly after discontinuation.

Study Design and Alternative Strategies Tested

This research followed 39 adults who had lost more than 10% of their body weight with GLP-1s and had ceased using them within the past month. Over four months, researchers compared three groups: a control group receiving standard care, a group using a digital wellness application (Noom), and a group receiving medically tailored meals (MTM). Participants weighed in using Bluetooth scales at the start and then every 30 days.

Understanding the Interventions

• Control Group: Fourteen participants continued with their usual medical care as directed by their doctors, without researcher intervention.
• Digital Wellness App (Noom): Twelve participants used Noom for at least 15 minutes per day. The app supports weight loss and weight maintenance through behavioral strategies, self-monitoring, and education on psychological, social, and environmental eating cues.
• Medically Tailored Meals (MTM): Thirteen participants received meals designed by dietitians, typically used for managing chronic diseases. MTM are nutrient-dense, portion-controlled, and lower in calories, sugar, sodium, and saturated fats.

Key Findings: Weighing the Results

Both intervention groups—MTM and the digital wellness application—experienced less weight regain compared to the control group. Over the four months:

• The control group regained about 10.75% of their weight.
• The Noom group regained 3.6% of their weight.
• The MTM group regained 3.58% of their weight.

Monthly rates of weight regain were also lower in the intervention groups, with the control group averaging a 2.94% monthly regain, while the MTM group averaged 0.61% and the Noom group 0.42%.

Understanding Weight Maintenance After Stopping Obesity Medication

The study highlights that weight maintenance after discontinuing obesity medication is affected by behavioral, physiological, social, and environmental factors. The interventions tested—digital wellness apps and MTM—target mechanisms believed to promote weight maintenance during the vulnerable period after GLP-1 use ends. Researchers note, "The digital wellness application focuses on self‐monitoring, behavior change skills, and management of social and environmental eating cues, whereas MTM modifies the food environment by reducing the meal planning burden and increasing access to portion‐controlled, nutrient‐dense meals."

Implications and Future Directions

The evidence suggests structured, nonpharmaceutical support may help mitigate rapid weight regain typically seen in the first months after ending GLP-1 use. The authors advise that more research over longer periods is needed to confirm the effectiveness of these weight maintenance strategies in supporting individuals after discontinuing GLP-1s. Early intervention appears to be crucial since weight is most often regained within three to four months post treatment.

Source: kfor.com.